

Brian A Jonas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4751692/publications.pdf>

Version: 2024-02-01

97
papers

5,052
citations

257357
24
h-index

95218
68
g-index

97
all docs

97
docs citations

97
times ranked

4962
citing authors

#	ARTICLE	IF	CITATIONS
1	Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. <i>Leukemia and Lymphoma</i> , 2022, 63, 231-234.	0.6	0
2	Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2022, 139, 1135-1146.	0.6	39
3	Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	8
4	Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. <i>Journal of Clinical Oncology</i> , 2022, 40, 855-865.	0.8	86
5	Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 71.	2.8	12
6	Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments. <i>OncoTargets and Therapy</i> , 2022, Volume 15, 423-436.	1.0	14
7	Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	5
8	Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center. <i>Leukemia Research</i> , 2022, 119, 106885.	0.4	2
9	Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-“PD-L1) Tj ETQq1 1 0.784314 rgBT /Over acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2711-2714.	0.6	6
10	Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. <i>American Journal of Hematology</i> , 2021, 96, 208-217.	2.0	95
11	Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. <i>Blood Cancer Journal</i> , 2021, 11, 5.	2.8	11
12	Phase <scp>l</scp> study of escalating doses of carfilzomib with <scp>HyperCVAD</scp> in patients with newly diagnosed acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2021, 96, E114-E117.	2.0	5
13	Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center. <i>Frontiers in Oncology</i> , 2021, 11, 649209.	1.3	36
14	An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2021, 14, 407-417.	1.0	0
15	A phase 1 study of the pan-“bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2943-2953.	2.0	42
16	Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 4726-4736.	3.2	1
17	Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e611-e618.	0.2	0
18	Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia. <i>Future Oncology</i> , 2021, 17, 2989-3005.	1.1	13

#	ARTICLE	IF	CITATIONS
19	Outcomes in Patients with Poor-Risk Cytogenetics with or without <i>TP53</i> Mutations Treated with Venetoclax Combined with Hypomethylating Agents. <i>Blood</i> , 2021, 138, 224-224.	0.6	16
20	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2020, 383, 617-629.	13.9	1,407
21	A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 453-458.	0.2	2
22	Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study. <i>Blood</i> , 2020, 136, 51-53.	0.6	10
23	CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study. <i>Blood</i> , 2020, 136, 50-52.	0.6	4
24	Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi). <i>Case Reports in Hematology</i> , 2020, 2020, 1-6.	0.3	2
25	Assessing the Quality of Electronic Data for 'Fit-for-Purpose' by Utilizing Data Profiling Techniques Prior to Conducting a Survival Analysis for Adults with Acute Lymphoblastic Leukemia. <i>AMIA ... Annual Symposium proceedings</i> , 2020, 2020, 915-924.	0.2	0
26	Complications in Acute Myeloid Leukemia Inductions Prior to Count Recovery: A Feasibility Study for Outpatient Care at an Academic Center. <i>Blood</i> , 2020, 136, 28-28.	0.6	0
27	HM43239, a Novel Small Molecule Inhibitor of FLT3, in Acute Myeloid Leukemia (AML) with and without FMS-like Tyrosine Kinase 3 (FLT3) Mutations: Phase 1/2 Study. <i>Blood</i> , 2020, 136, 1-1.	0.6	2
28	Delays in Time to Deterioration of Health-Related Quality of Life Were Observed in Patients with Acute Myeloid Leukemia Receiving Venetoclax in Combination with Azacitidine or in Combination with Low-Dose Cytarabine. <i>Blood</i> , 2020, 136, 33-35.	0.6	1
29	Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma. <i>Journal of the National Cancer Institute</i> , 2019, 111, 78-85.	3.0	20
30	A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, E291-E294.	2.0	11
31	Quizartinib in FLT3-ITD-Mutated Relapsed/Refractory Acute Myeloid Leukemia: QuANTUM-R Trial Results. <i>Annals of Oncology</i> , 2019, 30, vi81.	0.6	2
32	How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. <i>Leukemia</i> , 2019, 33, 2795-2804.	3.3	123
33	Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) â€“ Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S221-S222.	0.2	2
34	Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy</p> . <i>Core Evidence</i> , 2019, Volume 14, 3-17.	4.7	20
35	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 984-997.	5.1	330
36	Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 20, 102004.	1.7	21

#	ARTICLE	IF	CITATIONS
37	Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 509-515.e1.	0.2	15
38	Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science. <i>Toxics</i> , 2019, 7, 27.	1.6	7
39	Optimizing survival outcomes with postâ€remission therapy in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2019, 94, 803-811.	2.0	51
40	Venetoclax combined with decitabine or azacitidine in treatment-naïve, elderly patients with acute myeloid leukemia. <i>Blood</i> , 2019, 133, 7-17.	0.6	1,254
41	Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. <i>Blood</i> , 2019, 134, 229-229.	0.6	30
42	Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study. <i>Blood</i> , 2019, 134, 231-231.	0.6	23
43	Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis. <i>Blood</i> , 2019, 134, 760-760.	0.6	23
44	Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 539-539.	0.6	2
45	Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia. <i>Blood</i> , 2019, 134, 3897-3897.	0.6	5
46	Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Instituteâ€designated cancer centers in California. <i>Cancer</i> , 2018, 124, 1938-1945.	2.0	40
47	Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. <i>Lancet Oncology</i> , The, 2018, 19, 216-228.	5.1	551
48	Proteinuria, Hypoalbuminemia, and Chronic Lymphocytic Leukemia: An Unusual Trio. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2018, 6, 232470961876420.	0.3	1
49	Durable Response with Venetoclax in Combination with Decitabine or Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S201.	0.2	1
50	First-In-Human Study of ABBV-075 (Mivebresib), A Pan-Inhibitor of Bromodomain and Extra Terminal (BET) Proteins, in Patients (Pts) With Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML): Preliminary Data. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S203.	0.2	3
51	Toward Predicting Acute Myeloid Leukemia Patient Response to 7 + 3 Induction Chemotherapy via Diagnostic Microdosing. <i>Chemical Research in Toxicology</i> , 2018, 31, 1042-1051.	1.7	4
52	New and emerging therapies for acute myeloid leukaemia. <i>Journal of Investigative Medicine</i> , 2018, 66, 1088-1095.	0.7	21
53	Complications and early mortality in patients with acute promyelocytic leukemia treated in California. <i>American Journal of Hematology</i> , 2018, 93, E370-E372.	2.0	11
54	Novel drug combination unleashes apoptosis in AML. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	1

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial. Blood, 2018, 132, 563-563.	0.6	26
56	FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Aynndrome (MDS): Results from a Phase 1 Study. Blood, 2018, 132, 1452-1452.	0.6	16
57	Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses. Blood, 2018, 132, 331-331.	0.6	19
58	Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasana) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study. Blood, 2018, 132, 767-767.	0.6	21
59	Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy. Blood, 2018, 132, 285-285.	0.6	29
60	Retrospective Analysis of Adults with Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center. Blood, 2018, 132, 1424-1424.	0.6	4
61	A Phase II Study of Pegylated Asparaginase, Cyclophosphamide, Rituximab, and Dasatinib Added to the UCSF 8707 (Linker 4-drug) Regimen with Liposomal Cytarabine CNS Prophylaxis for Adults with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): University of California Hematologic Malignancies Consortium Study (UCHMC) 1401. Blood, 2018, 132, 4018-4018.	0.6	1
62	Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia. British Journal of Haematology, 2017, 177, 791-799.	1.2	43
63	Subsequent primary malignancies after diffuse large Bâ€cell lymphoma in the modern treatment era. British Journal of Haematology, 2017, 178, 72-80.	1.2	38
64	Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia. Case Reports in Hematology, 2017, 2017, 1-5.	0.3	5
65	Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance. Blood Cancer Journal, 2017, 7, e605-e605.	2.8	22
66	From MDS/AML to iPSC and back again. Science Translational Medicine, 2017, 9, .	5.8	2
67	Combination of an oncolytic virus with PD-L1 blockade keeps cancer in check. Science Translational Medicine, 2017, 9, .	5.8	14
68	On the origin of relapse in AML. Science Translational Medicine, 2017, 9, .	5.8	5
69	A new therapeutic target for myelofibrosis is cause for Gli. Science Translational Medicine, 2017, 9, .	5.8	1
70	â€œCHIPâ€s are bad for patients with solid tumors. Science Translational Medicine, 2017, 9, .	5.8	0
71	Just say NO to leaky bone marrow vasculature in AML. Science Translational Medicine, 2017, 9, .	5.8	0
72	Vascular endothelial cells take hematopoietic stem cells to school. Science Translational Medicine, 2017, 9, .	5.8	0

#	ARTICLE	IF	CITATIONS
73	Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity. PLoS ONE, 2016, 11, e0159189.	1.1	2
74	KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leukemia Research, 2016, 50, 123-131.	0.4	50
75	Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: A novel variant of myeloid proliferative neoplasm with eosinophilia. Human Pathology: Case Reports, 2016, 5, 6-9.	0.2	15
76	A Phase I/II Study of GMI-1271, a Novel E-Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date. Blood, 2016, 128, 4049-4049.	0.6	5
77	Racial/Ethnic and Socioeconomic Disparities in the Use of Autologous Hematopoietic Stem Cell Transplant (ASCT) Among Californians with Multiple Myeloma (MM). Blood, 2016, 128, 846-846.	0.6	3
78	Abstract 1313: Targeting micelles eradicate acute myeloid leukemia stem cells in a patient-derived leukemia xenograft model. , 2016, , .		0
79	Efficacy and Tolerability of Hyper-CVAD in Adult Acute Lymphoblastic Patients: A Retrospective Analysis at a Comprehensive Cancer Center. Blood, 2016, 128, 5195-5195.	0.6	0
80	Time to Treatment Initiation Predicts Overall Survival in Hospitalized Acute Myeloid Leukemia (AML) Patients: A California Population-Based Study. Blood, 2016, 128, 3982-3982.	0.6	2
81	Decreased Early Mortality Associated with Treatment of Acute Myeloid Leukemia (AML) at NCI-Designated Cancer Centers in California. Blood, 2016, 128, 391-391.	0.6	0
82	Acute Myeloid Leukemia with Isolated Trisomy 19 Associated with Diffuse Myelofibrosis and Osteosclerosis. Cancers, 2015, 7, 2459-2465.	1.7	2
83	Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome. Case Reports in Hematology, 2015, 2015, 1-5.	0.3	2
84	Optimal Molecular Methods in Detecting p190^{BCR-ABL} Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature. Case Reports in Hematology, 2015, 2015, 1-6.	0.3	12
85	MDS prognostic scoring systems – Past, present, and future. Best Practice and Research in Clinical Haematology, 2015, 28, 3-13.	0.7	42
86	B lymphoblastic leukemia with granules mimicking acute myeloid leukemia. International Journal of Hematology, 2015, 102, 251-252.	0.7	3
87	Paraneoplastic leukemoid reaction as a marker of tumor progression in non-small cell lung cancer. Cancer Treatment Communications, 2015, 4, 15-18.	0.4	12
88	Secondary Acute Lymphoblastic Leukemia (sALL) Is Associated with a Distinct Group of Primary Cancers and Has Prognostic Impact. Blood, 2015, 126, 1305-1305.	0.6	0
89	The Effect of Autologous Stem Cell Transplant (ASCT) on Survival in Californians with Multiple Myeloma (MM) in the Era of Modern Treatment. Blood, 2015, 126, 1991-1991.	0.6	0
90	Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin. Nanomedicine, 2014, 9, 1807-1820.	1.7	7

#	ARTICLE	IF	CITATIONS
91	Alternative mRNA Splicing of Corepressors Generates Variants That Play Opposing Roles in Adipocyte Differentiation. Journal of Biological Chemistry, 2011, 286, 44988-44999.	1.6	31
92	Response of SMRT (Silencing Mediator of Retinoic Acid and Thyroid Hormone Receptor) and N-CoR (Nuclear Receptor Corepressor) Corepressors to Mitogen-Activated Protein Kinase Kinase Kinase Cascades Is Determined by Alternative mRNA Splicing. Molecular Endocrinology, 2007, 21, 1924-1939.	3.7	34
93	KINASE SIGNALING AND ALTERNATIVE MESSENGER RIBONUCLEIC ACID SPLICING: TWO METHODS TO CUSTOMIZE SMRT AND N-COR FUNCTION WITHIN THE CELL.. Journal of Investigative Medicine, 2007, 55, S140.	0.7	0
94	Corepressors: Custom Tailoring and Alterations While you Wait. Nuclear Receptor Signaling, 2005, 3, nrs.03003.	1.0	58
95	Alternative mRNA Splicing of SMRT Creates Functional Diversity by Generating Corepressor Isoforms with Different Affinities for Different Nuclear Receptors. Journal of Biological Chemistry, 2005, 280, 7493-7503.	1.6	59
96	SMRT and N-CoR Corepressors Are Regulated by Distinct Kinase Signaling Pathways. Journal of Biological Chemistry, 2004, 279, 54676-54686.	1.6	76
97	DIFFERENTIAL REGULATION OF NUCLEAR COREPRESSOR PROTEINS, SILENCING MEDIATOR OF RETIONIC ACID AND THYROID HORMONE RECEPTORS AND NUCLEAR HORMONE RECEPTOR COREPRESSOR.. Journal of Investigative Medicine, 2004, 52, S146.	0.7	0